Novo Nordisk(US:NVO) Xin Hua Cai Jing·2025-11-06 10:52Core Viewpoint - The eighth China International Import Expo (CIIE) serves as a strategic platform for multinational companies, including Novo Nordisk, to solidify their market presence in China, particularly in chronic disease management and innovation [1] Group 1: Commitment to the Chinese Market - Novo Nordisk has been committed to the Chinese market since its entry in 1994, establishing a comprehensive local presence with over 19 billion RMB invested since 2003 [2] - The company has built a "three-engine" industrial chain in China, consisting of a production base in Tianjin, a research center in Beijing, and a commercial operation hub in Shanghai [3] Group 2: Innovation and Health Initiatives - Novo Nordisk aligns its mission to combat chronic diseases with China's "Healthy China 2030" initiative, focusing on innovation as a core contribution to the market [4] - The company has introduced 22 innovative drugs and 11 injection devices in China, particularly targeting diabetes and obesity, and has initiated the "China Co-Creation" project to synchronize clinical research [4][5] Group 3: Addressing Obesity Challenges - Obesity is recognized as a significant public health challenge in China, with 182 million adults affected, prompting government action to reduce obesity rates by 10% annually by 2026 [6][5] - Novo Nordisk's innovative products, including semaglutide, are positioned to address obesity and related chronic diseases, with a complete treatment matrix established [6][7] Group 4: Competitive Advantages - The company leverages its first-mover advantage and extensive experience in obesity treatment, alongside expanding its ecosystem through partnerships with online health platforms [7] - Semaglutide has gained global recognition, being named a "game changer" and receiving multiple awards for its innovative impact [7] Group 5: Role of CIIE - The CIIE acts as an accelerator for innovative drug launches, with Novo Nordisk showcasing 10 global innovative drugs over the past seven years [8] - The company plans to announce five significant collaborations at this year's expo, further enhancing its network in chronic disease management [10]